Isolated Hyperthermic Perfusions for Cutaneous Melanoma In-transit Metastasis of the Limb and Uveal Melanoma Metastasis to the Liver

Overview

Journal Clin Exp Metastasis

Specialty Oncology

Date 2023 Oct 16

PMID 37843790

Authors

Anne Huibers

Danielle K DePalo

Matthew C Perez

Jonathan S Zager

Roger Olofsson Bagge

Affiliations

Soon will be listed here.

Abstract

Patients with cutaneous melanoma can develop in-transit metastases (ITM), most often localized to limbs. For patients with uveal melanoma that develop metastatic disease, the overall majority develop isolated liver metastases. For these types of metastases, regional cancer therapies have evolved as effective treatments. Isolated limb perfusion (ILP), isolated limb infusion (ILI), isolated hepatic perfusion (IHP) and percutaneous hepatic perfusion (PHP) achieve a high local concentration of chemotherapy with minimal systemic exposure. This review discusses the mechanism and available literature on locoregional treatment modalities in the era of modern immunotherapy.

Citing Articles

Identification of Predictive Factors for the Development of In-Transit Metastasis in Patients with Melanoma.

Huibers A, Leong S, Kashani-Sabet M, White Jr R, Vetto J, Schneebaum S Ann Surg Oncol. 2025; .

PMID: 40064798 DOI: 10.1245/s10434-025-17084-4.

Isolated Limb Infusion as First, Second, or Third or Later-Line Therapy for Metastatic In-Transit Melanoma.

Boby A, Dugan M, Ghali H, Aflatooni S, DePalo D, Fan W Cancer Control. 2024; 31:10732748241297326.

PMID: 39500581 PMC: 11539175. DOI: 10.1177/10732748241297326.

ASO Author Reflections: Optimizing Line of Therapy with the Melphalan/Hepatic Delivery System for Metastatic Uveal Melanoma.

Ghali H, Dugan M, Zager J Ann Surg Oncol. 2024; 32(1):497-498.

PMID: 39196472 DOI: 10.1245/s10434-024-16112-z.

Hepatic and Overall Progression-Free Survival After Percutaneous Hepatic Perfusion (PHP) as First-Line or Second-Line Therapy for Metastatic Uveal Melanoma.

Ghali H, Dugan M, Aflatooni S, Boby A, DePalo D, Laborde J Ann Surg Oncol. 2024; 31(13):9150-9158.

PMID: 39174837 DOI: 10.1245/s10434-024-16039-5.

Clinical Characteristics and Special Considerations in the Management of Rare Melanoma Subtypes.

Shannon A, Zager J, Perez M Cancers (Basel). 2024; 16(13).

PMID: 39001457 PMC: 11240680. DOI: 10.3390/cancers16132395.

References

AUST J, AUSMAN R . The technique of liver perfusion. Cancer Chemother Rep. 1960; 10:23-33. View

. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol. 2001; 119(5):670-6. DOI: 10.1001/archopht.119.5.670. View

Michielin O, van Akkooi A, Ascierto P, Dummer R, Keilholz U . Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019; 30(12):1884-1901. DOI: 10.1093/annonc/mdz411. View

Muilenburg D, Beasley G, Thompson Z, Lee J, Tyler D, Zager J . Burden of disease predicts response to isolated limb infusion with melphalan and actinomycin D in melanoma. Ann Surg Oncol. 2014; 22(2):482-8. PMC: 4505812. DOI: 10.1245/s10434-014-4072-0. View

Andtbacka R, Collichio F, Harrington K, Middleton M, Downey G, hrling K . Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma. J Immunother Cancer. 2019; 7(1):145. PMC: 6554874. DOI: 10.1186/s40425-019-0623-z. View

Seth R, Messersmith H, Kaur V, Kirkwood J, Kudchadkar R, McQuade J . Systemic Therapy for Melanoma: ASCO Guideline. J Clin Oncol. 2020; 38(33):3947-3970. DOI: 10.1200/JCO.20.00198. View

Ariyan C, Brady M, Siegelbaum R, Hu J, Bello D, Rand J . Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade. Cancer Immunol Res. 2018; 6(2):189-200. PMC: 6857638. DOI: 10.1158/2326-6066.CIR-17-0356. View

Zaremba A, Philip M, Hassel J, Glutsch V, Fiocco Z, Loquai C . Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases. Eur J Cancer. 2021; 152:139-154. DOI: 10.1016/j.ejca.2021.04.032. View

Yang H, Dithmar S, Grossniklaus H . Interferon alpha 2b decreases hepatic micrometastasis in a murine model of ocular melanoma by activation of intrinsic hepatic natural killer cells. Invest Ophthalmol Vis Sci. 2004; 45(7):2056-64. DOI: 10.1167/iovs.03-1331. View

10.

Holmberg C, Ny L, Hieken T, Block M, Carr M, Sondak V . The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases - A multicenter cohort study. Eur J Cancer. 2022; 169:210-222. DOI: 10.1016/j.ejca.2022.03.041. View

11.

Davies E, Reijers S, van Akkooi A, van Houdt W, Hayes A . Isolated limb perfusion for locally advanced melanoma in the immunotherapy era. Eur J Surg Oncol. 2022; 48(6):1288-1292. DOI: 10.1016/j.ejso.2022.01.027. View

12.

Carr M, Sun J, Zager J . Isolated limb infusion: Institutional protocol and implementation. J Surg Oncol. 2020; 122(1):99-105. DOI: 10.1002/jso.25886. View

13.

AUSMAN R, AUST J . Isolated perfusion of the liver with HN2. Surg Forum. 1960; 10:77-9. View

14.

van Beek J, van den Bosch Q, Naus N, Paridaens D, de Klein A, Kilic E . Absence of Intraocular Lymphatic Vessels in Uveal Melanomas with Extrascleral Growth. Cancers (Basel). 2019; 11(2). PMC: 6406846. DOI: 10.3390/cancers11020228. View

15.

Raymond A, Beasley G, Broadwater G, Augustine C, Padussis J, Turley R . Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution. J Am Coll Surg. 2011; 213(2):306-16. PMC: 3143267. DOI: 10.1016/j.jamcollsurg.2011.03.013. View

16.

Robert C, Ribas A, Schachter J, Arance A, Grob J, Mortier L . Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019; 20(9):1239-1251. DOI: 10.1016/S1470-2045(19)30388-2. View

17.

Carvajal R, Sosman J, Quevedo J, Milhem M, Joshua A, Kudchadkar R . Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA. 2014; 311(23):2397-405. PMC: 4249701. DOI: 10.1001/jama.2014.6096. View

18.

Santillan A, Delman K, Beasley G, Mosca P, Hochwald S, Grobmyer S . Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis. Ann Surg Oncol. 2009; 16(9):2570-8. DOI: 10.1245/s10434-009-0563-9. View

19.

Pucci M, Moschetti M, Urzi O, Loria M, Conigliaro A, Di Bella M . Colorectal cancer-derived small extracellular vesicles induce TGFβ1-mediated epithelial to mesenchymal transition of hepatocytes. Cancer Cell Int. 2023; 23(1):77. PMC: 10114452. DOI: 10.1186/s12935-023-02916-8. View

20.

Diener-West M, Reynolds S, Agugliaro D, Caldwell R, Cumming K, Earle J . Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol. 2005; 123(12):1639-43. DOI: 10.1001/archopht.123.12.1639. View